US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Upsized IPO priced above expectations, with shares opening 37.5% above the IPO price despite significant early volatility.</li>
<li>Aggressive buying erased early losses, sending shares from near issue price to a 82% intraday gain.</li>
<li>Late-Stage clinical profile and favorable biotech sentiment continue supporting investor demand for quality healthcare IPOs.</li>
</ul>


Upsized IPO priced above expectations, with shares opening 37.5% above the IPO price despite significant early volatility.
Aggressive buying erased early losses, sending shares from near issue price to a 82% intraday gain.
Late-Stage clinical profile and favorable biotech sentiment continue supporting investor demand for quality healthcare IPOs.


Apnimed Inc. (APMD): Apnimed Awakens: Wild IPO Ride Ends with 56% First-Day Gain

<ul>
<li>Late-Stage biotech with a pending FDA review for Oxnimbi, a potential first oral therapy for obstructive sleep apnea.</li>
<li>Phase 3 success and NDA submission reduce development risk relative to earlier-stage biotech IPOs.</li>
<li>IPO is reportedly multiple-times oversubscribed, with strong support from healthcare specialists and crossover institutional investors.</li>
</ul>


Late-Stage biotech with a pending FDA review for Oxnimbi, a potential first oral therapy for obstructive sleep apnea.
Phase 3 success and NDA submission reduce development risk relative to earlier-stage biotech IPOs.
IPO is reportedly multiple-times oversubscribed, with strong support from healthcare specialists and crossover institutional investors.


Apnimed Inc. (APMD): "Waking Up" To the Next Late-Stage Biotech Story

Smartkarma AI IPO Databooks, Smartkarma

αSK IPO Databooks

Smartkarma AI IPO Databooks

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul><li><a href="https://smartkarma.com/entities/apnimed-inc" target="_blank">Apnimed</a>, Inc. is a late-stage clinical pharmaceutical company focused on novel oral therapies for sleep-related breathing diseases. Its sole clinical product candidate, Oxnimbi, is an investigational fixed-dose neuromuscular modulator for.</li><li>NDA for Oxnimbi was submitted to the FDA in April 2026 and accepted in July 2026. Oxnimbi met its primary endpoint in Phase 3 trials.</li><li>As of March 31, 2026, cash and cash equivalents were $46,886, with an accumulated deficit of $329,625. There is substantial doubt about the ability to continue as a going concern.</li></ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>

Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on novel oral therapies for sleep-related breathing diseases. Its sole clinical product candidate, Oxnimbi, is an investigational fixed-dose neuromuscular modulator for.NDA for Oxnimbi was submitted to the FDA in April 2026 and accepted in July 2026. Oxnimbi met its primary endpoint in Phase 3 trials.As of March 31, 2026, cash and cash equivalents were $46,886, with an accumulated deficit of $329,625. There is substantial doubt about the ability to continue as a going concern.This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

IPO Databook: Apnimed (APMD US) - Jul 2026

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>Apnimed (NASDAQ: APMD) is seeking to raise $150 million through the sale of 10.0 million shares priced between $14.00 and $16.00, implying a midpoint offering price of $15.00 per share.</li><li>At the midpoint, the company would command an estimated fully diluted market capitalization of approximately $570 million based on approximately 38.0 million shares outstanding after the offering. </li><li>The IPO is being led by BofA Securities, Evercore ISI, Cantor, and LifeSci Capital, with trading expected to begin Friday, July 31.</li></ul>

Apnimed (NASDAQ: APMD) is seeking to raise $150 million through the sale of 10.0 million shares priced between $14.00 and $16.00, implying a midpoint offering price of $15.00 per share.At the midpoint, the company would command an estimated fully diluted market capitalization of approximately $570 million based on approximately 38.0 million shares outstanding after the offering. The IPO is being led by BofA Securities, Evercore ISI, Cantor, and LifeSci Capital, with trading expected to begin Friday, July 31.

<ul><li>Apnimed is expected to list on the Nasdaq under the ticker APMD, offering 10.0 million shares at a price range of $14.00 to $16.00 per share, targeting approximately $150 million in gross proceeds.</li><li>The company is a late-stage biopharmaceutical developer focused on AD109, an investigational oral therapy for obstructive sleep apnea (OSA), a large and underserved market traditionally treated with CPAP devices.</li><li>The company recently received FDA acceptance of its New Drug Application (NDA) for AD109, with a PDUFA action date of February 28, 2027, representing a significant regulatory milestone.</li></ul>

Apnimed is expected to list on the Nasdaq under the ticker APMD, offering 10.0 million shares at a price range of $14.00 to $16.00 per share, targeting approximately $150 million in gross proceeds.The company is a late-stage biopharmaceutical developer focused on AD109, an investigational oral therapy for obstructive sleep apnea (OSA), a large and underserved market traditionally treated with CPAP devices.The company recently received FDA acceptance of its New Drug Application (NDA) for AD109, with a PDUFA action date of February 28, 2027, representing a significant regulatory milestone.

United States

Apnimed, Inc. is a pharmaceutical company. The Company focuses on the discovery, development, and commercialization of oral therapies that address the neurobiology of sleep-related breathing diseases. Apnimed operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Apnimed (APMD US)

Apnimed Inc. (APMD): Apnimed Awakens: Wild IPO Ride Ends with 56% First-Day Gain

Strong investor demand for quality healthcare IPOs drives shares of upsized IPO to open 37.5% above price, with aggressive buying leading to an...

IPO Boutique

Apnimed Inc. (APMD): "Waking Up" To the Next Late-Stage Biotech Story

Late-stage biotech company set for FDA review of potential first oral therapy for obstructive sleep apnea, IPO oversubscribed with reduced...

IPO Boutique

IPO Databook: Apnimed (APMD US) - Jul 2026

Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on novel oral therapies for sleep-related breathing diseases. Its sole...

αSK IPO Databooks

Apnimed (APMD) Eyes $150 Million IPO

Apnimed (NASDAQ: APMD) is seeking to raise $150 million through the sale of 10.0 million shares priced between $14.00 and $16.00, implying a...

IPO Prophet

Apnimed Inc: IPO Prophet Rating: 7.80/10

Apnimed is expected to list on the Nasdaq under the ticker APMD, offering 10.0 million shares at a price range of $14.00 to $16.00 per share,...

IPO Prophet

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Apnimed Inc. (APMD): Apnimed Awakens: Wild IPO Ride Ends with 56% First-Day Gain

​Strong investor demand for quality healthcare IPOs drives shares of upsized IPO to open 37.5% above price, with aggressive buying leading to an...

IPO Boutique

Apnimed Inc. (APMD): "Waking Up" To the Next Late-Stage Biotech Story

​Late-stage biotech company set for FDA review of potential first oral therapy for obstructive sleep apnea, IPO oversubscribed with reduced...

IPO Boutique

IPO Databook: Apnimed (APMD US) - Jul 2026

Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on novel oral therapies for sleep-related breathing diseases. Its sole...

αSK IPO Databooks

Apnimed (APMD) Eyes $150 Million IPO

Apnimed (NASDAQ: APMD) is seeking to raise $150 million through the sale of 10.0 million shares priced between $14.00 and $16.00, implying a...

IPO Prophet

Apnimed Inc: IPO Prophet Rating: 7.80/10

Apnimed is expected to list on the Nasdaq under the ticker APMD, offering 10.0 million shares at a price range of $14.00 to $16.00 per share,...

IPO Prophet

Strong investor demand for quality healthcare IPOs drives shares of upsized IPO to open 37.5% above price, with aggressive buying leading to an...

Late-stage biotech company set for FDA review of potential first oral therapy for obstructive sleep apnea, IPO oversubscribed with reduced...